Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 17Unknown 5Withdrawn 4Terminated 3Recruiting 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Dermatologic 1

Conditions

Epitheliod Malignant Pleural Mesothelioma 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 224Cyclophosphamide 192Radiotherapy 183Nivolumab 180Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 104Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 91Ipilimumab 81Doxorubicin 79Lenalidomide 76durvalumab 75Rituximab 75atezolizumab 72Radiation 72venetoclax 69fludarabine 68Standard of Care 68Gemcitabine 68Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT05020912 2026-06-01

Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

Case Comprehensive Cancer Center

Phase 2 Active not recruiting
18 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT02153229 2025-12-26

MPM-PDT

Abramson Cancer Center at Penn Medicine

Phase 2 Active not recruiting
52 enrolled
Other solid neoplasmThoracic

Epitheliod Malignant Pleural Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡